![Christian Bailey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christian Bailey
Private Equity Investor bei UP Partners Management Co. LLC
Aktive Positionen von Christian Bailey
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
UP Partners Management Co. LLC
![]() UP Partners Management Co. LLC Investment ManagersFinance UP Partners Management Co. LLC (UP Partners) is a venture capital firm founded in 2019 by Cyrus Sigari and Ben Marcus. The firm is headquartered in Santa Monica, California. | Private Equity Investor | 01.07.2020 | - |
Karriereverlauf von Christian Bailey
Ehemalige bekannte Positionen von Christian Bailey
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Vorstandsvorsitzender | 01.06.2010 | 01.12.2011 |
Gründer | 01.06.2010 | 01.12.2011 | |
Lincoln Asset Management Group LLC
![]() Lincoln Asset Management Group LLC Investment ManagersFinance Founded by Christian Bailey, Lincoln Asset Management Group LLC is a hedge fund manager located in New York City. They manage the Lincoln Vector Fund LP and the Lincoln Futures Fund. | Chief Investment Officer | - | - |
Portfolio Manager-Aktien | - | - | |
Präsident | - | - | |
incTANK Inc
![]() incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Private Equity Investor | 08.12.2010 | - |
Ausbildung von Christian Bailey
University of Oxford | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Vereinigtes Königreich | 2 |
Operativ
Private Equity Investor | 2 |
Chief Investment Officer | 1 |
Portfolio Manager-Equities | 1 |
Sektoral
Finance | 4 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Lincoln Asset Management Group LLC
![]() Lincoln Asset Management Group LLC Investment ManagersFinance Founded by Christian Bailey, Lincoln Asset Management Group LLC is a hedge fund manager located in New York City. They manage the Lincoln Vector Fund LP and the Lincoln Futures Fund. | Finance |
incTANK Inc
![]() incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Finance |
UP Partners Management Co. LLC
![]() UP Partners Management Co. LLC Investment ManagersFinance UP Partners Management Co. LLC (UP Partners) is a venture capital firm founded in 2019 by Cyrus Sigari and Ben Marcus. The firm is headquartered in Santa Monica, California. | Finance |
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Commercial Services |
- Börse
- Insiders
- Christian Bailey
- Erfahrung